Evaluation of Pericardial Effusions in Alopecia Patients on Low-Dose Oral Minoxidil Therapy.

IF 1.5 4区医学 Q3 DERMATOLOGY

Journal of Drugs in Dermatology Pub Date : 2024-09-01 DOI:10.36849/JDD.8029

Colin M Kincaid, Ajay N Sharma, Brynn Sargent, Irmina Gradus-Pizlo, Elizabeth H Dineen, Natasha A Mesinkovska

{"title":"Evaluation of Pericardial Effusions in Alopecia Patients on Low-Dose Oral Minoxidil Therapy.","authors":"Colin M Kincaid, Ajay N Sharma, Brynn Sargent, Irmina Gradus-Pizlo, Elizabeth H Dineen, Natasha A Mesinkovska","doi":"10.36849/JDD.8029","DOIUrl":null,"url":null,"abstract":"Background: Minoxidil is an anti-hypertensive vasodilator increasingly used off-label for the treatment of alopecia. It is associated with an increased risk of pericardial effusions, with recent reports even in patients on low-dose oral minoxidil (LDOM) therapy.Objective: To evaluate whether LDOM is associated with increased prevalence of pericardial effusions in patients with alopecia.Methods: In this cross-sectional study, point-of-care ultrasound was used to screen alopecia patients at dermatology appointments. Scans were evaluated by two independent cardiologists for the presence and size of effusions. The prevalence of effusions was compared between patients on LDOM therapy and patients not on minoxidil therapy.Results: A total of 100 patients were evaluated for pericardial effusion: 51 LDOM patients and 49 control patients. The two groups were similar in terms of age (53.7 vs 54.1; P=0.91), sex (86% vs 73% female; P=0.14), and race. Small pericardial effusions (<1 cm) were identified in 5.8% of LDOM patients and 6% of control patients (P=1), none of which were symptomatic.Limitations: This is a small, cross-sectional study with limitations on speculation of causality in confirmed cases.Conclusion: We did not find evidence of increased prevalence of pericardial effusions in a small group of alopecia patients on LDOM. J Drugs Dermatol. 2024;23(9):725-728. doi:10.36849/JDD.8029.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"23 9","pages":"725-728"},"PeriodicalIF":1.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8029","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Minoxidil is an anti-hypertensive vasodilator increasingly used off-label for the treatment of alopecia. It is associated with an increased risk of pericardial effusions, with recent reports even in patients on low-dose oral minoxidil (LDOM) therapy.

Objective: To evaluate whether LDOM is associated with increased prevalence of pericardial effusions in patients with alopecia.

Methods: In this cross-sectional study, point-of-care ultrasound was used to screen alopecia patients at dermatology appointments. Scans were evaluated by two independent cardiologists for the presence and size of effusions. The prevalence of effusions was compared between patients on LDOM therapy and patients not on minoxidil therapy.

Results: A total of 100 patients were evaluated for pericardial effusion: 51 LDOM patients and 49 control patients. The two groups were similar in terms of age (53.7 vs 54.1; P=0.91), sex (86% vs 73% female; P=0.14), and race. Small pericardial effusions (<1 cm) were identified in 5.8% of LDOM patients and 6% of control patients (P=1), none of which were symptomatic.

Limitations: This is a small, cross-sectional study with limitations on speculation of causality in confirmed cases.

Conclusion: We did not find evidence of increased prevalence of pericardial effusions in a small group of alopecia patients on LDOM. J Drugs Dermatol. 2024;23(9):725-728. doi:10.36849/JDD.8029.

查看原文本刊更多论文

对接受小剂量米诺地尔口服疗法的脱发患者心包积液的评估

背景：米诺地尔是一种抗高血压血管扩张剂，越来越多地在标签外用于治疗脱发。它与心包积液的风险增加有关，最近甚至有报道称小剂量口服米诺地尔（LDOM）治疗的患者也会出现心包积液：评估 LDOM 是否与脱发患者心包积液发病率增加有关：在这项横断面研究中，在皮肤科就诊时使用护理点超声波筛查脱发患者。由两名独立的心脏病专家对扫描结果进行评估，以确定是否存在积液以及积液的大小。对接受 LDOM 治疗的患者和未接受米诺地尔治疗的患者的渗出率进行了比较：共有100名患者接受了心包积液评估：51名LDOM患者和49名对照组患者。两组患者在年龄（53.7 岁 vs 54.1 岁；P=0.91）、性别（86% 女性 vs 73%；P=0.14）和种族方面相似。在5.8%的LDOM患者和6%的对照组患者（P=1）中发现了小量心包积液（1厘米），其中无症状：这是一项小型横断面研究，对确诊病例的因果关系推测存在局限性：结论：我们没有发现服用 LDOM 的一小部分脱发患者心包积液发病率增加的证据。J Drugs Dermatol.2024;23(9):725-728. doi:10.36849/JDD.8029.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drugs in Dermatology DERMATOLOGY-

CiteScore

2.20

自引率

13.30%

发文量

289

审稿时长

3-6 weeks

期刊介绍： The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.